Edition:
India

Aduro Biotech Inc (ADRO.OQ)

ADRO.OQ on NASDAQ Stock Exchange Global Select Market

2.53USD
11:05pm IST
Change (% chg)

$-0.04 (-1.56%)
Prev Close
$2.57
Open
$2.61
Day's High
$2.61
Day's Low
$2.48
Volume
31,328
Avg. Vol
149,176
52-wk High
$4.04
52-wk Low
$0.90

Latest Key Developments (Source: Significant Developments)

Aduro Biotech Says On Jan 22, Co Appointed William Kachioff As Interim CFO
Friday, 24 Jan 2020 

Jan 23 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH- ON JAN 22, CO APPOINTED WILLIAM G. KACHIOFF AS INTERIM CHIEF FINANCIAL OFFICER -SEC FILING.  Full Article

Aduro Biotech Posts Q2 Loss Per Share Of $0.23
Friday, 2 Aug 2019 

Aug 1 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 REVENUE $4.9 MILLION VERSUS $2.6 MILLION.Q2 LOSS PER SHARE $0.23.Q2 REVENUE ESTIMATE $10.1 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.18 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $251.6 MILLION AT JUNE 30, 2019, COMPARED TO $277.9 MILLION AT DECEMBER 31, 2018.QTRLY REVENUE WAS $4.9 MILLION VERSUS $2.6 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.18, REVENUE VIEW $10.1 MILLION -- REFINITIV IBES DATA.  Full Article

Aduro Biotech And Novartis Present Results From Ongoing Phase 1B Study
Sunday, 2 Jun 2019 

June 2 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH AND NOVARTIS PRESENT RESULTS FROM ONGOING PHASE 1B STUDY OF STING AGONIST ADU-S100 (MIW815) IN COMBINATION WITH ANTI-PD-1 MONOCLONAL ANTIBODY SPARTALIZUMAB (PDR001) IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMAS.ADURO BIOTECH- AS OF APRIL 5, FIVE PATIENTS TREATED IN WEEKLY DOSING SCHEDULE GROUP ACHIEVED CONFIRMED RESPONSES, ONE OF WHICH WAS COMPLETE RESPONSE.  Full Article

Aduro Biotech Reports Q1 Loss Per Share $0.29
Wednesday, 8 May 2019 

May 7 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.29.Q1 REVENUE $3.9 MILLION VERSUS $6.6 MILLION.Q1 REVENUE ESTIMATE $8.9 MILLION -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE ESTIMATE $-0.19 -- REFINITIV IBES DATA.  Full Article

Aduro Biotech Reports Fourth Quarter And Full Year 2018 Financial Results
Thursday, 28 Feb 2019 

Feb 27 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 REVENUE $2.8 MILLION VERSUS $3.8 MILLION.Q4 REVENUE ESTIMATE $4.3 MILLION -- REFINITIV IBES DATA.QTRLY LOSS PER SHARE $0.33.Q4 EARNINGS PER SHARE VIEW $-0.23 -- REFINITIV IBES DATA.Q4 REVENUE VIEW $4.3 MILLION -- REFINITIV IBES DATA.  Full Article

Aduro Biotech Announces Strategic Reset
Wednesday, 30 Jan 2019 

Jan 30 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH ANNOUNCES STRATEGIC RESET.ADURO BIOTECH INC - AS A RESULT OF STRATEGIC RESET, ADURO HAS REDUCED ITS CURRENT WORKFORCE BY APPROXIMATELY 37 PCT.ADURO BIOTECH INC - REDUCTION IN ONGOING OPERATING EXPENSES IS EXPECTED TO EXTEND COMPANY'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES INTO 2022.ADURO BIOTECH INC - ADURO ENDED 2018 WITH $277.9 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.ADURO BIOTECH INC - REDUCTION IN ONGOING OPERATING EXPENSES IS EXPECTED TO EXTEND CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES INTO 2022.  Full Article

BRIEF-Aduro Biotech Announces First Patient Dosed In Phase 1 Study Of Bion-1301 In Iga Nephropathy

* ADURO BIOTECH ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY OF BION-1301 IN IGA NEPHROPATHY Source text for Eikon: Further company coverage: